Drug Profile
Research programme: antibody-drug conjugates - Innate Pharma/Sanofi
Alternative Names: Anticancer therapeutics - Innate Pharma/SanofiLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Innate Pharma; Sanofi
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Natural cytotoxicity triggering receptor 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Cancer in France
- 09 Feb 2016 Sanofi and Innate Pharma enter into a research and licensing agreement utlising Innate Pharma’s proprietary technology to develop bispecific antibody conjugates for Cancer
- 16 Apr 2015 Innate Pharma and Sanofi enter into collaboration to develop antibody-drug conjugates for Cancer